Results 111 to 120 of about 24,047,971 (353)

Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies

Frontiers in Oncology, 2021
Carlos Pérez-Plasencia, Carlos Pérez-Plasencia, Teresita Padilla-Benavides, Eduardo López-Urrutia, Alma D. Campos-Parra   +4 more
doaj   +1 more source

Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma

Pharmaceutics
Objectives: This in vivo study introduces a newly developed spirooxindole derivative that is deemed safe and effective as a potential targeted therapy for various cancers.
Assem Barakat, Fardous F. El-Senduny, Mohammad Shahidul Islam, Abdullah Mohammed Al-Majid, Yaseen A. M. M. Elshaier, Eman A. Mazyed, Farid A. Badria   +6 more
doaj   +1 more source

Radioimmunotheragnosis in Cancer Research

Cancers
The combination of immunoPET—where an antibody (Ab) is labeled with an isotope for PET imaging—and radioimmunotherapy (RIT), using the same antibody with a therapeutic isotope, offers significant advantages in cancer management.
Guillermo Garaulet, Bárbara Beatriz Báez, Guillermo Medrano, María Rivas-Sánchez, David Sánchez-Alonso, Jorge L. Martinez-Torrecuadrada, Francisca Mulero   +6 more
openaire   +2 more sources

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Recent Research on Cancer [PDF]

, 1936
J. P. Lockhart-Mummery
openalex   +1 more source

Statistical Researches on Cancer [PDF]

The American Journal of the Medical Sciences
n ...
openaire   +2 more sources

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

The future of multimodal artificial intelligence models for integrating imaging and clinical metadata: a narrative review

Diagnostic and Interventional Radiology
With the ongoing revolution of artificial intelligence (AI) in medicine, the impact of AI in radiology is more pronounced than ever. An increasing number of technical and clinical AI-focused studies are published each day.
Benjamin D. Simon, Kutsev Bengisu Ozyoruk, David G. Gelikman, Stephanie A. Harmon, Barış Türkbey   +4 more
doaj   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Editorial: Clinical cancer research in vulnerable populations

Frontiers in Oncology, 2023
Laura Tack, Laura Tack, Patricia Schofield, Tom Boterberg, Christopher N. Parris, Philip R. Debruyne, Philip R. Debruyne, Philip R. Debruyne   +7 more
doaj   +1 more source